bisaramil

Known as: syn-3-ethyl-7-methyl-3,7-diazabicyclo(3.3.1)non-9-yl p- chlorobenzoate, yutac 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1990-1999
012319901999

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
The effects of bisaramil, a novel diazabicyclononane antiarrhythmic agent, were compared to those of lidocaine, a clinically used… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1997
1997
The aim of this study was to investigate the effect of bisaramil--an antiarrhythmic drug under clinical trials-on free radical… (More)
Is this relevant?
1997
1997
The aim of this study was to investigate the effect of bisaramil--an antiarrhythmic drug under clinical trials--on free radical… (More)
Is this relevant?
1996
1996
The aim of this study was to determine whether bisaramil-an antiarrhythmic compound under clinical investigation-influences the… (More)
Is this relevant?
1995
1995
Antiarrhythmic effects of bisaramil were examined by using new in vivo triggered arrhythmia models, and they were compared with… (More)
Is this relevant?
1993
1993
The antiarrhythmic effects of bisaramil were examined in canine models of digitalis-, adrenaline- and two-stage coronary ligation… (More)
Is this relevant?
1993
1993
Six healthy volunteers received an oral dose of 100 mg and an intravenous dose of 35 mg of bisaramil in a cross over study… (More)
Is this relevant?
1992
1992
A column liquid chromatographic method using electrochemical detection has been developed for determination of an antiarrhythmic… (More)
Is this relevant?
1991
1991
Bisaramil is a new, orally active antiarrhythmic agent. We investigated and classified its mechanism of action according to… (More)
Is this relevant?
1990
1990
Antiarrhythmic activity of bisaramil (3-methyl,7-ethyl,9 alpha, 4'-(Cl-benzoyloxy)-3,7-diazabicyclo[3.3.1.]nonane… (More)
Is this relevant?